Search results
'Outstanding' 5 Year PFS With Lorlatinib in ALK+ NSCLC
Medscape· 3 days agoFive-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.
The Real ‘Deep State’
The Atlantic· 5 days agoOn March 18, news broke that Donald Trump intended to restore the disgraced lobbyist Paul Manafort to the ranks of his campaign advisers. Back in 2016,...